Home › Myelodysplastic Syndromes › Arizona › Scottsdale
Myelodysplastic Syndromes clinical trials in Scottsdale, AZ
3 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Scottsdale (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RecruitingPhase 1
- Mayo Clinic in Arizona, Scottsdale
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Scottsdale
Q702 for the Treatment of Patients With Hematologic Malignancies
RecruitingPhase 1
- Mayo Clinic in Arizona, Scottsdale
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA26 studies
- New York City, NY21 studies
- Seattle, WA21 studies
- Washington, DC20 studies
- Tampa, FL19 studies
- Boston, MA19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- Durham, NC14 studies
- St. Louis, MO13 studies
- Atlanta, GA13 studies
Other studies in Scottsdale
- Breast Cancer18 studies
- Cancer (all types)18 studies
- Metastatic Cancer17 studies
- Prostate Cancer17 studies
- Colorectal Cancer16 studies
- Non-Small Cell Lung Cancer15 studies
- Pancreatic Cancer13 studies
- Melanoma10 studies
- Ulcerative Colitis8 studies
- Lung Cancer8 studies
- Liver Cancer (Hepatocellular Carcinoma)7 studies
- Alzheimer's Disease7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.